• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$1.46 $0.09 (6.57%)

REAL-TIME: Last trade at

ACADIA Pharmaceuticals, Inc.

NASDAQ:ACAD

Acadia Pharmaceuticals initiated with a Buy at Roth Capital

22 Biopharma Stocks With Breakout Potential in 2012

ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012

ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012

ACADIA Pharmaceuticals Reports First Quarter 2012 Financial Results

Acadia Pharmaceuticals, Inc. (ACAD) Posts Q1 Loss of 12c/Share

Acadia Pharmaceuticals reports Q1 EPS (12c), consensus (11c)

ACADIA Pharmaceuticals Reports First Quarter 2012 Financial Results

ACADIA Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012

ACADIA Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012

On The Fly: Analysts Initiation Summary

Ladenburg Thalmann Starts Acadia Pharmaceuticals (ACAD) at Buy

Acadia Pharmaceuticals initiated with a Buy at Ladenburg

ACADIA Pharmaceuticals to Present at the 19th Annual Future Leaders in the Biotech Industry Conference on April 20, 2012

ACADIA Pharmaceuticals to Present at the 19th Annual Future Leaders in the Biotech Industry Conference on April 20, 2012

ACADIA Loses Steam As Volume Plummets

ACADIA Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference on April 3, 2012

ACADIA Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference on April 3, 2012

ACADIA Pharmaceuticals Awarded New Grant from The Michael J. Fox Foundation for Development of Nurr1-RXR Selective Agonists to Treat Parkinson’s Disease

Acadia Pharmaceuticals awarded new grant from Michael J. Fox Foundation

ACADIA Pharmaceuticals Awarded New Grant from The Michael J. Fox Foundation for Development of Nurr1-RXR Selective Agonists to Treat Parkinson’s Disease

8 Stocks Under $10 Moving Higher

Acadia Pharmaceuticals rises 16%

5 Stocks Under $5 Making Big Moves

Acadia Pharmaceuticals: Could Be Another Ariad

Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); Q4 Review: Pimavanserin Study 020 Results Expected in Late 3Q12

Acadia Pharmaceuticals reports Q4 EPS (10c), consensus (10c)

Companies reporting After the Market Close on Tuesday, March 6

Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q4 Loss

ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011

ACADIA Pharma (ACAD) Extends Drug Discovery Collaboration With Allergan (AGN) For Glaucoma

ACADIA Pharma (ACAD), Allergan (AGN) Expand Ophthalmic Indication Discovery Collaboration

Acadia Pharmaceuticals announces extension of Allergan collaboration

ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.

ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences

ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2011 Financial Results on March 6, 2012

ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012

ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012

ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors

ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors

See More Articles...